Fig. 4. Determinants of Covid-19 vaccine response in patients with CLL.
A Paired analysis of antibody responses to SARS-CoV-2 Spike in healthy donors (HD) and patients with CLL after first and second vaccine (Analysis by TBS ELISA, HD median post 1st and 2nd vaccine 1.0 & 5.8 vs CLL median 0.5 & 3.0, respectively) with cut off for positivity shown by dotted line ratio = 1). B Dot plot showing antibody responses to second vaccine in patients with CLL taking a Bruton Tyrosine Kinase inhibitor (BTKi) and those not on BTKi (median BTKi 0.6 vs No BTKi 3.2 p = 0.0002) as measured by TBS assay. C Correlation between antibody response to SARS-CoV-2 following second vaccine and serum immunoglobulin. Antibody levels were measured by TBS ELISA and shown against total serum IgA (p = 0.0004; r = 0.43, IgA deficiency (0.8 g/L) is highlighted in blue); total serum IgG (p = 0.02; r = 0.29, IgG deficiency (6 g/L) highlighted in blue) and total serum IgM (p = 0.01, r = 0.334, IgM deficiency (<0.5 g/L) highlighted in blue). D Infographic of patients with CLL according to the presence or absence of antibody response following double vaccination according to disease characteristics (n = 55).